Abstract: The present disclosure provides a backlight compensation method, device and system, and a storage medium. The method is used to compensate brightness of a plurality of mini-LEDs in a backlight unit, where the plurality of mini-LEDs include M rows and N columns, and both M and N are positive integers greater than 1, and the method includes: acquiring a control signal for controlling the brightness of the backlight unit, and acquiring a row compensation value corresponding to mini-LEDs in each row and a column compensation value corresponding to mini-LEDs in each column; compensating the mini-LEDs in each row and the mini-LEDs in each column according to the row compensation value and the column compensation value, to obtain a compensated control signal; and controlling the brightness of the backlight unit according to the compensated control signal.

Abstract: A control method for a backlight circuit includes: obtaining a plurality of pieces of dimming data in a preset period of time; determining total accumulated electric energy received by the backlight source according to the plurality of pieces of dimming data in the preset period of time; and generating a first voltage control signal when the total accumulated electric energy reaches a preset electric energy threshold. The dimming data is used to control a backlight source to emit light. The preset period of time is from an initial moment of continuous light emission of the backlight source to a current moment. The first voltage control signal is used to reduce the working voltage of the backlight source. When the total accumulated electric energy reaches the preset electric energy threshold, reducing the working voltage of the backlight source does not affect a light emitting brightness of the backlight source.

Abstract: Provided are an LED control system, a device, a method and a storage medium. The system includes: a controller and a plurality of cascaded LED drivers, where the controller is configured to: send a data signal to the plurality of cascaded LED drivers, the data signal includes data packets corresponding to the plurality of LED drivers arranged in sequence, and each LED driver corresponds to a data packet that includes control data and an end bit corresponding to the LED driver. The LED driver is configured to: acquire control data of a preset length from the controller or a previous LED driver, and detect whether the end bit is a preset value; if the end bit is the preset value and there is a next LED driver, transmit a data signal after the end bit to the next driver.

Abstract: The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and/or treating myocardial infarction, a use in manufacture of a medicament for preventing and/or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and/or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and/or treatment of salt-sensitive hypertensive myocardial fibrosis.

Abstract: The present invention relates to a use of cellular repressor of E1A-stimulated genes (CREG) protein, and in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The present invention also relates to a use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for the prevention and/or treatment of a fatty liver disease and type 2 diabetes. The invention also relates to a corresponding kit, such as a kit used for the predication and/or evaluation of therapeutic effect and prognosis of a fatty liver disease and type 2 diabetes.

Abstract: Described is the use of an E1A activating gene repressor (CREG) protein, in particular to a use of a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases. Also described is the use of a recombinant vector or recombinant cell expressing a CREG protein or an active fragment thereof in manufacture of a medicament for prevention and/or treatment of overweight, obesity, insulin resistance, hyperlipidemia and related diseases.

Abstract: The present invention relates to a medical use of Cellular Repressor of E1A-stimulated Genes (CREG), in particular to a use of CREG protein or active fragment thereof in manufacture of a medicament for preventing and/or treating myocardial infarction, a use in manufacture of a medicament for preventing and/or treating ventricular remodeling after myocardial infarction and heart failure after myocardial infarction, a use in manufacture of a medicament for prevention and/or treatment of myocardial ischemia-reperfusion injury, a use in manufacture of a medicament for prevention and/or treatment of salt-sensitive hypertensive myocardial fibrosis.